Saturday, 10 October 2026European Markets

FAGRON Stock Impressive Jump 16% On Thursday, Outperforms Market

Loading stream...

(VIANEWS) - Shares of FAGRON (BEL 20: FAGR.BR) rose by a staggering 16.09% to 15.15 € at 16:12 EST on Thursday, following the last session's downward trend. BEL 20 is rising 0.59% to 3,924.69 €, following the last session's upward trend. This seems, so far, a somewhat up trend trading session today.

About FAGRON

Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it supplies raw materials, utensils and equipment, semi-finished products, vehicles, and sterile and non-sterile compounded medicines. Further, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. It has operations in Latin America, North America, Europe, the Middle East, and Africa. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Earnings Per Share

As for profitability, FAGRON has a trailing twelve months EPS of 0.82 €.

PE Ratio

FAGRON has a trailing twelve months price to earnings ratio of 18.48. Meaning, the purchaser of the share is investing 18.48 € for every euro of annual earnings.

Volatility

FAGRON's last week, last month's, and last quarter's current intraday variation average was a negative 0.31%, a negative 0.37%, and a positive 1.03%.

FAGRON's highest amplitude of average volatility was 0.66% (last week), 0.90% (last month), and 1.03% (last quarter).

More news about FAGRON (FAGR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com